AUREON Biosciences and Comprehensive Medical Center, PLLC Announce “Partners against Prostate Cancer” Community Outreach Program

Share Article

Commencing this September, Prostate Cancer Awareness Month, Aureon and CMC will embark on a number of initiatives and events in the greater Detroit area to educate primary-care physicians and their patients of the latest advances in prostate cancer management.

"CMC was the first urology practice in the greater Detroit area to use Prostate Px+ and Post-Op Px prognostic prostate cancer technology demonstrating their commitment to using the latest advances in personalized, prognostic tools.”

Comprehensive Medical Center (CMC), Royal Oak, Michigan, and Aureon Biosciences are pleased to announce the Partners against Prostate Cancer Community Outreach Program. Commencing this September, Prostate Cancer Awareness Month, Aureon and CMC will embark on a number of initiatives and events in the greater Detroit area to educate primary-care physicians and their patients of the latest advances in prostate cancer management.

“The constant flow of new technology and research means the management of prostate cancer is always evolving” said Dr. Donald Moylan, President of CMC. “It is our mission to provide patients with state-of-the-art technology and Partners against Prostate Cancer is a great vehicle to educate the community on the latest advances in prostate cancer management.

“CMC was the first urology practice in the greater Detroit area to use Aureon’s Prostate Px+ and Post-Op Px prognostic prostate cancer technology demonstrating their commitment to using the latest advances in personalized, prognostic tools” said Dr. Jason Alter, V.P. of Marketing for Aureon. “These tests analyze a patient’s tumor at the cellular and molecular level to provide an unprecedented level of information to physicians and their patients. We are pleased to be partnering with CMC and other institutions across the country to educate the community on the latest advances in prostate cancer risk assessment.”

Each year approximately 240,000 new cases of prostate cancer are diagnosed. There are a number of treatment options available. The primary objective of the Partners against Prostate Cancer program is to educate patients and primary care physicians on the latest prognostic information available to help them make more-informed decisions regarding their treatment. Aureon Biosciences is partnering with CMC and other leaders in the Urology community throughout 2011-2012 to implement this new educational program.

About Comprehensive Medical Center

Comprehensive Medical Center is Michigan’s leading large urology group dedicated to excellence in patient care with integrity and compassion while supporting urologic research and education. Comprehensive Medical Center is committee to provide convenient, expedited and cost effective urologic care applying best practice protocols and state-of-the-art technology. For more information about Comprehensive Medical Center please visit http://www.urologist.org or call media contact Lyndie Krystopowicz-Marcoux at 248-336-3399.

About Aureon Biosciences

Aureon’s personalized, prognostic tools provide objective, comprehensive risk assessment both at diagnosis and after surgery. Prostate Px+ uses biopsy tissue at diagnosis to predict clinically significant disease as well as possible pathology changes post-surgery and is especially helpful for patients classified as low or intermediate risk. Post-Op Px provides objective information for post-surgical patients with a high risk feature (e.g., positive surgical margin, extracapsular extension) or any anxiety.

Aureon Biosciences mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput systems pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA-certified and CAP-accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, please visit http://www.aureon.com or call 1-888-SYS-PATH

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dr. Charles J. DiComo
Aureon Biosciences, Inc.
(914) 377-4005
Email >
Visit website

Media